Ryan D. Maynard - 23 Feb 2026 Form 4 Insider Report for Foghorn Therapeutics Inc. (FHTX)

Role: Chief Financial Officer
Signature: /s/ Michael LaCascia, Attorney-in-Fact for Ryan D. Maynard
Issuer symbol: FHTX
Transactions as of: 23 Feb 2026
Net transactions value: +$2,300,000
Form type: 4
Filing time: 24 Feb 2026, 16:02:39 UTC
Previous filing: 17 Jun 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Maynard Ryan D	Chief Financial Officer	99 COOLIDGE AVENUE, SUITE 500, WATERTOWN	/s/ Michael LaCascia, Attorney-in-Fact for Ryan D. Maynard	24 Feb 2026	0001363984

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	FHTX	Stock Option (right to buy)	Award	$2,300,000	+400,000		$5.75	400,000	23 Feb 2026	Common Stock	400,000	$5.75	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option vests as to 25% of the underlying shares of common stock on February 23, 2027, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter until the option is fully vested.